Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance).
Publication
, Journal Article
Edelman, MJ; Wang, X; Hodgson, L; Cheney, RT; Baggstrom, MQ; Sachdev, T; Gajra, A; Bertino, EM; Reckamp, KL; Molina, J; Schiller, J; Ritter, J ...
Published in: Int J Radiat Oncol Biol Phys
May 1, 2017
Duke Scholars
Published In
Int J Radiat Oncol Biol Phys
DOI
EISSN
1879-355X
Publication Date
May 1, 2017
Volume
98
Issue
1
Start / End Page
220 / 221
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Edelman, M. J., Wang, X., Hodgson, L., Cheney, R. T., Baggstrom, M. Q., Sachdev, T., … Vokes, E. E. (2017). Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance). Int J Radiat Oncol Biol Phys, 98(1), 220–221. https://doi.org/10.1016/j.ijrobp.2017.01.038
Edelman, M. J., X. Wang, L. Hodgson, R. T. Cheney, M. Q. Baggstrom, T. Sachdev, A. Gajra, et al. “Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance).” Int J Radiat Oncol Biol Phys 98, no. 1 (May 1, 2017): 220–21. https://doi.org/10.1016/j.ijrobp.2017.01.038.
Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Sachdev T, et al. Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance). Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):220–1.
Edelman, M. J., et al. “Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance).” Int J Radiat Oncol Biol Phys, vol. 98, no. 1, May 2017, pp. 220–21. Pubmed, doi:10.1016/j.ijrobp.2017.01.038.
Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Sachdev T, Gajra A, Bertino EM, Reckamp KL, Molina J, Schiller J, Mitchell-Edwards K, Friedman P, Ritter J, Milne G, Stinchcombe TE, Hahn O, Vokes EE. Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance). Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):220–221.
Published In
Int J Radiat Oncol Biol Phys
DOI
EISSN
1879-355X
Publication Date
May 1, 2017
Volume
98
Issue
1
Start / End Page
220 / 221
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- 5105 Medical and biological physics
- 3407 Theoretical and computational chemistry
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 0299 Other Physical Sciences